We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+5.67%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$191M
AUM Growth
+$6.1M
Cap. Flow
+$4.9M
Cap. Flow %
2.56%
Top 10 Hldgs %
79.09%
Holding
32
New
3
Increased
11
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$10.4M
2
SBBP
Strongbridge Biopharma plc.
SBBP
+$7.55M
3
CHMA
Chiasma, Inc. Common Stock
CHMA
+$6.89M
4
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$3.4M
5
GYRE icon
Gyre Therapeutics
GYRE
+$2.87M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$5.82M
2
DMAC icon
DiaMedica Therapeutics
DMAC
+$4.95M
3
APEN
Apollo Endosurgery, Inc.
APEN
+$4.71M
4
PLXP
PLx Pharma Inc. Common Stock
PLXP
+$4.57M
5
ADMS
Adamas Pharmaceuticals
ADMS
+$3.75M

Sector Composition

Rank Sector Weight
1 Healthcare 88.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCYX icon
26
SCYNEXIS
SCYX
$35.5M
$1K ﹤0.01%
+13
New +$820
APVO icon
27
Aptevo Therapeutics
APVO
$5.25M
– –
0
– -$1.18M
AYTU icon
28
AYTU BioPharma
AYTU
$22.1M
– –
-18,146
Closed -$2.76M
BWAY
29
Brainsway
BWAY
$632M
– –
-110,362
Closed -$498K
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
– –
-10,000
Closed -$771K
PLXP
31
DELISTED
PLx Pharma Inc. Common Stock
PLXP
– –
-506,274
Closed -$4.57M
ONCS
32
DELISTED
OncoSec Medical Incorporated
ONCS
– –
-4,308
Closed -$452K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Stonepine Capital Management held 32 positions worth $191M, up 3.3% from $185M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Stonepine Capital Management's Q2 2021 filing shows 3 new, 11 increased, 12 reduced and 5 closed positions. Its largest new stake was Cidara Therapeutics: 60,564 shares worth $2.45M. The largest sale was KalVista Pharmaceuticals, an estimated $5.82M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2021 buy was Cidara Therapeutics: 60,564 shares worth $2.45M.
  • Stonepine Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2021, an estimated $10.4M increase.
  • Stonepine Capital Management's biggest Q2 2021 reduction was KalVista Pharmaceuticals, cutting an estimated $5.82M.
  • Stonepine Capital Management fully exited PLx Pharma Inc. Common Stock in Q2 2021, selling an estimated $4.57M.
  • Stonepine Capital Management's ten largest holdings make up 79% of its $191M portfolio in Q2 2021.
  • Stonepine Capital Management opened 3 new positions and closed 5 in Q2 2021.
  • Stonepine Capital Management's portfolio value rose 3.3% quarter-over-quarter to $191M.

Based on Stonepine Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.